ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more
The Moving Average Convergence Divergence (MACD) for ADMA turned positive on July 09, 2025. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ADMA's RSI Oscillator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where ADMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 09, 2025. You may want to consider a long position or call options on ADMA as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .
ADMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
ADMA moved below its 50-day moving average on June 13, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ADMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.834) is normal, around the industry mean (17.292). P/E Ratio (22.036) is within average values for comparable stocks, (58.926). ADMA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.456). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (9.891) is also within normal values, averaging (272.270).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
WMKGX | 23.84 | -0.08 | -0.33% |
WesMark Large Company Fund | |||
JORRX | 19.74 | -0.09 | -0.45% |
Janus Henderson Global Select R | |||
IAXTX | 9.56 | -0.08 | -0.83% |
VY® T. Rowe Price Divers Mid Cap Gr S2 | |||
TCIWX | 26.38 | -0.24 | -0.90% |
Nuveen International Eq Idx W | |||
HUSEX | 28.10 | -0.27 | -0.95% |
Huber Small Cap Value Instl |
A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with IOVA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then IOVA could also see price increases.
Ticker / NAME | Correlation To ADMA | 1D Price Change % | ||
---|---|---|---|---|
ADMA | 100% | +0.22% | ||
IOVA - ADMA | 45% Loosely correlated | -3.11% | ||
TARS - ADMA | 44% Loosely correlated | N/A | ||
IMTX - ADMA | 41% Loosely correlated | -0.50% | ||
ACLX - ADMA | 41% Loosely correlated | +0.17% | ||
KRYS - ADMA | 39% Loosely correlated | -1.05% | ||
More |